A5043645919- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- HER2/EGFR in Cancer Research
- Economic and Financial Impacts of Cancer
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Advanced Radiotherapy Techniques
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging Techniques and Applications
- Nanoplatforms for cancer theranostics
Merck & Co., Inc., Rahway, NJ, USA (United States)
2022-2024
In an interim analysis of this phase 3 trial, the addition pembrolizumab to chemotherapy resulted in longer progression-free survival than alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) a combined positive score (CPS; number PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by total viable multiplied 100) 10 or more. The results final overall have not been reported.
503 Background: KEYNOTE-522 (NCT03036488) tested the benefit from adding pembrolizumab (pembro) to chemotherapy (chemo) in patients (pts) with early TNBC. The primary results showed statistically significant and clinically meaningful improvements pCR EFS pembro.Prior studies have shown prognostic value of residual cancer burden (RCB) method quantify extent disease after neoadjuvant chemo. In this exploratory analysis, we assessed by RCB KEYNOTE-522. Methods: 1174 pts previously untreated,...
Pembrolizumab plus chemotherapy improved progression-free survival (PFS) and overall (OS) compared with placebo in patients previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer tumor programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥10 the global, phase 3, randomized controlled trial KEYNOTE-355. We report results for enrolled Japan. Patients were 2:1 to pembrolizumab 200 mg Q3W 35 cycles (nab-paclitaxel, paclitaxel,...
Abstract Background: In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) followed by adjuvant pembro showed statistically significant and clinically meaningful improvements in pathological complete response (pCR) event-free survival (EFS) compared with placebo (pbo) chemo pbo patients (pts) early-stage triple-negative breast cancer (TNBC). Here, we present updated EFS results after a median follow-up of ~5 y. Methods: Eligible pts previously untreated,...
The randomized phase III KEYNOTE-522 trial demonstrated that addition of pembrolizumab to neoadjuvant chemotherapy provided a significant improvement in event-free survival and favorable trend overall for high-risk early-stage triple-negative breast cancer (eTNBC). This analysis evaluated the cost-effectiveness combination with as treatment continued single-agent adjuvant after surgery vs. patients eTNBC USA.The was conducted from US third-party public healthcare payer perspective. A...
In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant significantly improved pathological complete response event-free survival vs in early-stage triple-negative breast cancer (TNBC). We report patient-reported outcomes (PROs) from KEYNOTE-522. Patients were randomized 2:1 to 200 mg or placebo every 3 weeks, 4 cycles of paclitaxel carboplatin doxorubicin (or epirubicin) cyclophosphamide. After surgery, patients received for up 9 cycles. European...
Objective: This study evaluated the cost–effectiveness of pembrolizumab/chemotherapy combinations for previously untreated metastatic triple-negative breast cancer patients in USA with PD-L1 combined positive score ≥10. Methods: A partitioned-survival model was developed to project health outcomes and direct medical costs over a 20-year time horizon. Efficacy safety data were from randomized clinical trials. Comparative effectiveness indirect comparators assessed using network meta-analyses....
Abstract Background: The phase 3 KEYNOTE-522 study (NCT03036488) showed that pembrolizumab (pembro) administered in combination with neoadjuvant chemotherapy (chemo) and then continued as adjuvant monotherapy resulted statistically significant clinically meaningful improvements pathological complete response (pCR) event-free survival (EFS) patients early triple-negative breast cancer (TNBC). In this post hoc analysis, we assessed outcomes by patterns of radiation therapy (RT) administration....
Abstract Background: In the phase 3 KEYNOTE-355 trial (NCT02819518), pembrolizumab (pembro) combined with chemotherapy (chemo) showed statistically significant improvements in OS and PFS compared to placebo + chemo patients previously untreated locally recurrent inoperable or metastatic TNBC whose tumors expressed PD-L1 a positive score (CPS) ≥10. There were no differences between treatment groups CPS ≥1 population, statistical significance was not tested ITT population due prespecified...
Abstract Background: KEYNOTE-522 (NCT03036488) is a phase 3 study of neoadjuvant pembro + chemo vs placebo chemo, followed by adjuvant in patients with early-stage TNBC. The primary analysis showed statistically significant and clinically meaningful improvement event-free survival (EFS) pembro. To assess the robustness consistency EFS result, prespecified sensitivity subgroup analyses for were performed. Methods: Patients previously untreated, non-metastatic, centrally confirmed TNBC (stage...
Abstract Background: In KEYNOTE-355 (NCT02819518), pembrolizumab (pembro) + chemotherapy (chemo) led to statistically significant and clinically meaningful improvements in PFS OS (primary endpoints) vs placebo (pbo) chemo patients (pts) with previously untreated PD-L1 positive advanced TNBC (combined score ≥10). the overall safety population at final analysis, treatment-related AEs occurred 96.3% of pts pembro arm 95.0% pbo arm; immune-mediated 26.5% 6.4% pts, respectively. We report...
Abstract Background: In KEYNOTE-522 (NCT03036488), neoadjuvant (neoadj) pembrolizumab (pembro) + chemotherapy (chemo) followed by adjuvant (adj) pembro led to statistically significant and clinically meaningful improvements in the primary endpoints, pCR EFS, vs neoadj placebo (pbo) chemo adj pbo patients (pts) with newly diagnosed, high-risk, early TNBC. safety population at preplanned interim analysis 4 (IA4), treatment-related AEs combined phases (neoadj adj) occurred 98.9% of pts...
"HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis" published on 31 Mar 2022 by National Comprehensive Network.